Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2025)

Entrada Therapeutics has reported Current Deferred Revenue over the past 3 years, most recently at $351000.0 for Q3 2025.

  • Quarterly results put Current Deferred Revenue at $351000.0 for Q3 2025, down 95.59% from a year ago — trailing twelve months through Sep 2025 was $351000.0 (down 95.59% YoY), and the annual figure for FY2024 was $6.5 million, down 95.08%.
  • Current Deferred Revenue for Q3 2025 was $351000.0 at Entrada Therapeutics, up from $194000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for TRDA hit a ceiling of $148.5 million in Q1 2024 and a floor of $194000.0 in Q2 2025.
  • Median Current Deferred Revenue over the past 3 years was $10.5 million (2023), compared with a mean of $53.7 million.
  • Biggest five-year swings in Current Deferred Revenue: grew 21.35% in 2024 and later plummeted 99.8% in 2025.
  • Entrada Therapeutics' Current Deferred Revenue stood at $132.3 million in 2023, then tumbled by 95.08% to $6.5 million in 2024, then crashed by 94.61% to $351000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $351000.0 (Q3 2025), $194000.0 (Q2 2025), and $301000.0 (Q1 2025) per Business Quant data.